Cann Group (ASX:CAN) - CEO, Peter Crock
CEO, Peter Crock
Source: Cannabis Club Australia
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Medical cannabis company Cann Group (CAN) has announced that investor Aurora Cannabis has dropped its stake in the company
  • Aurora sold its 11.84 per cent shareholding in Cann via off-market trades to a small number of buyers
  • Aurora said its plan to sell is consistent with its current strategic priorities
  • Nevertheless, Cann has reassured shareholders that Aurora’s decision will not impact its business plans
  • On the market today, Cann is down 7.14 per cent, trading for 39 cents per share

Medical cannabis company Cann Group (CAN) has announced that investor Aurora Cannabis has dropped its stake in the company.

On Friday, Aurora sold its 11.84 per cent shareholding in Cann via off-market trades to a small number of buyers.

Aurora said its plan to sell is consistent with its current strategic priorities.

Nevertheless, Cann has reassured shareholders that Aurora’s decision will not impact its business plans.

Currently, the company is “developing a growing and diversified supply base with business to business (B2B) customers in Australia and overseas and proceeding with plans to expand its manufacturing capacity.”

In August, the company’s 2020 financial year results came out. Cann’s full-year revenue slipped 56 per cent to $1.86 million compared to the previous financial year.

With the Mildura facility expansion, Cann is expecting around $15 million in revenue for the 2021 financial year.

On the market today, Cann is down 7.14 per cent, trading for 39 cents per share at 12:31pm AEDT.

can by the numbers
More From The Market Online
Close up of CSL sign on the office building in Melbourne, Victoria, Australia.

CSL profit drop only deepens what has already been grim reporting week

CSL Ltd has backed up its chaotic Tuesday – where the board dumped Paul McKenzie –…

Paradigm Biopharmaceuticals to boost oral treatment of osteoarthritis for animals

Paradigm Biopharmaceuticals (ASX: PAR) is co-developing a novel oral combination therapy for the treatment of osteoarthritis…
MEG scan concept AI gen

Compumedics snags sixth order for Orion LifeSpan at $4.2M heading to Shandong

Compumedics has inked a fresh $4.2M order to kick off CY26 with a sixth unit of…
A woman with a sign and a sad face

Last year’s anti-sweat biotech darling Botanix falls -10% on poorly received quarterly

Botanix Pharma (ASX:BOT) saw its share price fall around -10% on Tuesday as the company’s latest quarterly update, in